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Insulin therapyAims: We aimed to review insulin dosing recommendations, insulin regulation and its
determinants, glycaemic response to carbohydrates, and the efficacy and safety of insulin
therapy in different races/ethnicities.
Methods: We searched for articles in PubMed and Google Scholar databases up to 31 March
2021, with the following keywords: ‘‘ethnicity”, ‘‘diabetes”, ‘‘insulin”, ‘‘history of insulin”,
‘‘insulin therapy”, ‘‘food/rice”, ‘‘carbohydrate intake”, ‘‘insulin resistance”, ‘‘BMI”, ‘‘insulin
dosing”, ‘‘insulin sensitivity”, ‘‘insulin response”, ‘‘glycaemic index”, ‘‘glycaemic response”,
‘‘efficacy and safety”, with interposition of the Boolean operator ‘‘AND”. In addition, we
reviewed the reference lists of the articles found.
Results: The differential effect of race/ethnicity has not yet been considered in current
insulin therapy guidelines. Nevertheless, body size and composition, body mass index,
fat distribution, diet, storage, and energy expenditure vary significantly across populations.
Further, insulin sensitivity, insulin response, and glycaemic response to carbohydrates
2 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 5 ( 2 0 2 1 ) 1 0 8 8 2 3differ by ethnicity. These disparities may lead to different insulin requirements, adversely
impacting the efficacy and safety of insulin therapy among ethnic groups.
Conclusions: Race/ethnicity affects glucose metabolism and insulin regulation. Until now,
international guidelines addressing racial/ethnic-specific clinical recommendations are
limited. Comprehensive updated insulin therapy guidelines by ethnicity are urgently
needed.
 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes is a major public health challenge of the 21st cen-
tury. Currently, around 463 million people (20–79 years) live
with diabetes, which corresponds to 9.3% of the global popu-
lation. By 2045, this number is expected to rise to 700 million.
Formerly considered ‘‘a disease of the wealthy”, approxi-
mately 80% of those with diabetes now live in low- and
middle-income countries [1]. Although diabetes is common
across the world, ethnic disparities have been consistently
reported in relation to diabetes prevalence and incidence,
pathophysiology, mortality, and acute and long-term compli-
cations [1–3].
Several studies on racial differences in diabetes have
shown higher prevalence and incidence rates among non-
white populations [2,4,5]. Although the exact reasons remain
unknown, these disparities likely emanate from multiple fac-
tors, including genetic, epigenetic, different pathophysiologi-
cal patterns, lifestyle, and environment [2]. Worldwide,
Hispanic, and Asian populations present a higher prevalence
of diabetes than Europeans and Africans both in their native
settings and among their diaspora [1,6]. Evidence suggests
that the genetic background of Africans and East Asians
makes them more and differentially susceptible to diabetes
than Caucasians [7]. Diabetes prevalence also differs consid-
erably among Hispanic and non-Hispanic Asian subgroups
in the United States [4,6]. In a nationally representative survey
of US adults from 2011 to 2016, the prevalence of diabetes was
12.1% for non-Hispanic white (NHW), whereas it was signifi-
cantly higher for non-Hispanic black (NHB) (20.4%), Hispanic
(22.1%), and non-Hispanic Asian adults (19.1%) [2].
The literature shows that non-Caucasians have higher
mortality rates and risk of diabetes complications, after
adjusting for confounders [8]. Approximately 4.2 million peo-
ple died of diabetes in 2019, with marked heterogeneity
across the globe. According to the International Diabetes Fed-
eration (IDF), death rates attributable to diabetes varied from
6.8% in sub-Saharan Africa, to 8.5% in Europe, around 11% in
the Western Pacific region, almost 13% in South and Central
America, approximately 14% in the North America, Carib-
bean, and South East Asia regions, and 16.2% in Middle East
and North Africa [1]. In the US, NHB are 2.3 times more likely
to die from diabetes than NHW, whereas the figures for Native
Americans and Hispanics are 1.9 and 1.5x. Furthermore,
Native Hawaiians and Filipinos living in Hawaii are 5.7 and
3.0 times more likely to die from diabetes than NHW [9]. Evenin modern societies where diabetes care is available and
accessible for great portion of the population, both micro-
and macrovascular complications related to diabetes differ
significantly among ethnic groups. Although a lower risk of
cardiovascular disease (CVD) has been reported for ethnic
minorities in the US, several studies suggest that Native
Americans, Hispanics and NHB have an increased risk for
lower extremity amputations than NHW [10]. Furthermore,
Asians in the UK and the Netherlands, as well as Hispanics
and blacks in the US have shown a higher risk of nephropathy
and end-stage renal disease. Ethnic minorities in the US also
seem to present an increased risk of retinopathy, whereas
Algerians in France have a higher risk of neuropathy [8].
Differences in responsiveness to medicinal products have
been commonly observed across ethnic groups. Although
insulin has been applied in the treatment of diabetes for
100 years, scarce evidence exists regarding potential ethnic
differences in response to insulin dosing and formulations.
It has been reported that West African descendants (including
African Americans and native Ghanaians) have higher
degrees of insulin resistance than Caucasians [11,12]. Simi-
larly, despite a higher average energy and fat intake, NHW
have also shown lower insulin resistance than Hispanics
[13]. Those ethnic differences in insulin sensitivity may affect
recommendations on treatment type and dosage. Even
though in insulin therapy the dose is individually titrated
according to patients’ needs and lifestyle, the recommended
starting dose may vary across ethnic groups. Therefore, we
aimed to review insulin dosing recommendations, insulin
regulation and its determinants, glycaemic response to carbo-
hydrates, and efficacy and safety of insulin therapy in differ-
ent races/ethnicities.
2. Methods
A literature review was carried out to search for articles in
PubMed and Google Scholar databases up to 31 March 2021.
The following keywords were used: ‘‘ethnicity”, ‘‘diabetes”,
‘‘insulin”, ‘‘history of insulin”, ‘‘insulin therapy”, ‘‘food/rice”,
‘‘carbohydrate intake”, ‘‘insulin resistance”, ‘‘BMI”, ‘‘insulin
dosing”, ‘‘insulin sensitivity”, ‘‘insulin response”, ‘‘glycaemic
index”, ‘‘glycaemic response”, ‘‘efficacy and safety”, with
interposition of the Boolean operator ‘‘AND”. Further, we
retrieved the full text of relevant studies in the reference lists
of the searched articles. Only articles in English were
considered.
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In 1889, two German researchers, Oskar Minkowski and
Joseph von Mering, found that when the pancreas gland
was removed from dogs, the animals developed symptoms
of diabetes and died soon afterward. This led to the idea that
the pancreas was the site where ‘‘pancreatic substances” (in-
sulin) were produced. In 1921, inspired by Mering’ and Min-
kowki’s studies, Paulescu performed a pancreatectomy in a
dog, emulsified the pancreatic tissue and injected it into the
jugular vein of the animal. He demonstrated that this pancre-
atic extract had an anti-diabetic effect [14].
In 1922, for the first time in the history of medicine, an
insulin extract was administered to a 14-year-old boy in Tor-
onto General Hospital. Nevertheless, this clinical experimen-
tation was a failure. Following further refinements, a second
series of injections effectively controlled glycaemia, glyco-
suria, and ketonuria. This marked the first successful
administration of insulin to a type 1 diabetes patient and,
ultimately, led to the development of commercially available
insulin [15].
Important progress has been made over the last hundred
years. The structure of insulin was delineated in 1955. In
1967, proinsulin was discovered and the radioimmunoassay
for C-peptide was developed. In 1972, the U100 insulin was
introduced to promote better accuracy in administration,
and, in 1982, recombinant human insulin became available.
In the 1990s, insulin pen delivery devices became available,
followed by the discovery of short (1996) and long (2001) act-
ing insulin analogues [14].
2.2. Insulin dosing: Formulae and challenges in different
ethnic groups
Given the progressive nature of type 2 diabetes mellitus
(T2DM), many patients eventually require and benefit from
insulin therapy. According to the American Diabetes Associa-
tion (ADA) [16], insulin for T2DM may be started to augment
therapy with oral agents. Currently, basal insulin alone is a
usual regimen applied in clinical practice. Starting doses
can be estimated based on body weight (0.1–0.2 units/kg/day)
and the degree of hyperglycaemia. Alternatively, ten units of
basal insulin once daily can be added, with individualized
titration over days to weeks as needed. Some individuals
may also require doses of insulin before meals to reach gly-
caemic targets. Usually, a dose of 4 units or 10% of the amount
of basal insulin at the largest meal or the meal with the high-
est postprandial excursion is applied for initiating therapy. In
metabolically stable type 1 diabetes patients or those with
T2DM who require replacement therapy, total daily insulin
requirements are also estimated by the weight, with doses
ranging from 0.4 to 1.0 units/kg/day (0.5 units/kg/day is a typ-
ical starting dose, with 50% of the daily dose as basal insulin
and 50% as prandial). The longer-acting basal dose regulates
overnight, fasting glucose, whereas shorter acting formula-
tions control postprandial glucose levels. Current recommen-
dations for prandial insulin dose are individualized based on
carbohydrate intake, premeal glucose levels, and anticipated
activity [16]. Nevertheless, specific features of insulin resis-tance, insulin secretion, and glycaemic response to carbohy-
drates in different populations have not yet been addressed
in the formulae.
Historically, dosing guidelines have been based on clinical
experience and retrospective studies of patients. The first for-
mula proposed in 1922 was also weight based and calculated
conservatively to prevent hypoglycaemia and preserve the
limited amount of insulin available (Dose (ml) = body
weight  insulin sensitivity of dogs / 2) [17]. In 1982, based
upon clinical experience with human regular insulin, Skyler
et al. [18] suggested that the total basal dose (TBD) should
be about 40% of the total daily dose (TDD). In 1998, the ‘‘rule
of 3” was proposed for estimating carbohydrate-to-insulin
ratio (CIR = [3  weight in lb]/TDD) [19]. Current formulae
for estimating the correction factor (CF) are based on the sug-
gestion by Davidson et al. [19] of the ‘‘1500 rule”, later modi-
fied to ‘‘1700” (CF = 1700/TDD). These three formulae
together became the foundation of the Accurate Insulin Man-
agement system. Subsequently, Walsh et al. [20], using retro-
spective pump download information, suggested that the CIR
should be calculated from 450/TDD. Since the previous for-
mulae had been based on regular insulin used in pump treat-
ment, Walsh et al. proposed a modification to CF = 2000/TDD.
Walsh essentially agreed with Davidson that the formula for
estimating the CIR should be CIR=(2.6  weight in lb)/TDD,
reflecting the widespread use of rapid-acting insulin analogs
(see Table 1 for a detailed description of the parameters used
in the formulae) [20].
Currently, a consensus statement from the American
Association of Clinical Endocrinologists/American College of
Endocrinology [22], recommends the following formulae:
TBD (U) = 50% of TDD, CIR = 450/TDD, and CF = 1700/TDD.
Nevertheless, independent studies in Japan and the US using
more rigorous designs suggested that traditional formulae
overestimated basal insulin requirements and underesti-
mated bolus requirements [23]. Results from the US showed
that the TBD should be 40% of the TDD, whereas data from
Japan reported a more appropriate TBD of 30% of the TDD.
The Japanese diet with higher-carbohydrate and lower-fat
proportions than the US diet possibly explains this difference.
Further, Japanese studies also found that the CIR exhibited
diurnal variability ranging from 300/TDD at breakfast to 400/
TDD for lunch or dinner [23]. Hypothetical calculation has
shown that the currently used formulae for estimating the
CIR and CF may lead to underdosing of bolus insulin by as
much as 12.8–50% [21].
High-fat, low-carbohydrate intake reduces the ability of
basal insulin to suppress hepatic glucose production [24].
Since the American diet has higher-carbohydrate and lower-
fat proportions, it could be assumed that the US recommen-
dations for basal dose would be higher than in countries with
lower-fat content in their diet. For the Asian Indian diet [25]
(consisting of 78% carbohydrates and 13% fat), for instance,
the total bolus dose should be much higher than the US diet,
but the total basal dose would be less. Therefore, it is possible
that the recommended TBD to be 50% of the TDD may be
excessive for India, China, and other countries of similar diet
composition [21]. The TBD/TDD ratio of < 30% in the Japanese
studies supports this contention [23].
Table 1 – Definition of parameters used in insulin dosing formulae [21].
Parameters Definitions
TDD The total basal and prandial insulin dosage.
TBD The fraction of TDD given as basal insulin.
CIR A number that, when divided into the number of grams of ingested carbohydrates, indicates the units of insulin needed to lower blood glucose to a pre-meal
value within 2–4 h.
CF A number that, when divided into the difference between actual and target blood glucose, yields the number of extra units of insulin needed to lower blood
glucose to the target range, within 2–4 h.
CF: correction factor, CIR: carbohydrate-to-insulin ratio, TBD: total basal dose, TDD: total daily dose















































Fig. 1 – Ethnic differences in the relationship between
insulin sensitivity and insulin response in normal glucose
tolerance (NGT) cohorts. Scatter plot of insulin sensitivity
index (SI) vs. acute insulin response to glucose (AIRg)
measured in healthy African, Caucasian, and East Asian
cohorts. Each circle corresponds to one study cohort. Each
circle area is proportional to the cohort sample size. The
solid line is the curve calculated in the meta-analysis of
Kodama et al. [7] [ln(AIRg) = –0.915  ln(SI) – 2.82]. The
dashed line is the curve of Kahn et al. [26] describing healthy
Caucasians [ln(AIRg) = –1.0  ln(SI) – 3.80]. Figure by Kodama
et al. Non-commercial creative commons license.
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from newer studies may be due to the more rigorous design
of the latter. International differences in diet composition
may also be important to consider when developing insulin
dosing recommendations.
2.3. Evolutionary roots of race/ethnic disparities in
glucose metabolism and insulin regulation
It has been hypothesized that depending on a population’s
genetic or evolutionary history, ethnic differences exist in
the optimal states of glucose metabolism and insulin regula-
tion. Human blood glucose levels have likely evolved toward
their current equilibrium over thousands of years. As a
response to genetic or environmental perturbations, the sta-
bility of blood glucose regulation has developed through a
hyperbolic function of two variables: insulin sensitivity and
insulin response [26,27]. Global migration in ancient days
placed people in new environments, under different climate
conditions, food availability and exposure to pathogens.
These changes may have made some adjustments in factors
that influence insulin sensitivity and secretion, such as body
size and composition, energy expenditure, storage, and heat
production. As these factors altered, novel genetic variations
or mutations may have pushed some subpopulations to dif-
ferent points of stability [7,27].
Studies have found ethnic differences in the stabilization
points of insulin sensitivity and insulin response to maintain
the normal blood glucose levels. It has been observed that
Africans have significantly lower insulin sensitivity and
higher insulin response to glucose than Caucasians and East
Asians. In contrast, East Asians present higher insulin sensi-
tivity and lower insulin response than the other two groups
[7]. In a meta-analysis of 74 study cohorts, Kodama et al. [7]
calculated the hyperbolic relationship between insulin sensi-
tivity and insulin response in three different populations.
They used the mean values of the insulin sensitivity index
(SI) and acute insulin response to glucose (AIRg) in normal
glucose tolerance (NGT) cohorts and stratified distributions
by ethnicity. As shown in Fig. 1, Caucasians clustered around
the middle of the hyperbola, whereas African and East Asian
subpopulations were in unstable extreme points in the curve.
In these areas, small changes in one variable are associated
with large nonlinear changes in the other variable. Therefore,
it may be hypothesized that, in Africans, even a slight
increase in insulin resistance in current days could lead to a
rapid increase in the amount of insulin secretion necessary
to maintain NGT [7]. Interestingly, it has been reported that
African Americans have a twofold increased risk of develop-
ing T2DM compared with Caucasians [28]. On the other hand,
given the observed limited capacity of insulin secretion in
East Asians [29], it can also be speculated that even a small
decrease in insulin secretion may lead to a rapid decrease
in the threshold level of insulin resistance above which
T2DM arises. This may possibly contribute to the high preva-
lence of diabetes in East Asia nowadays [7].
In any population, genetic predisposition, and environ-
mental triggers likely account for the development of T2DM.
The ‘‘thrifty genotype” hypothesis proposes that individuals
with certain genetically driven metabolic features might havebeen selected for survival. In primeval times, when food avail-
ability was insecure, those who were metabolically ‘‘thrifty”
had better odds of survival. When food was available,
metabolic thriftiness ensured efficient storage of energy for
use during famine. Nevertheless, with urbanization and
immigration, now this genotype predisposes individuals to
insulin resistance and diabetes [3,30]. In the early 1990s, Hales
and Barker et al. [31] formulated an alternative explanation
for the origins of T2DM, metabolic syndrome and CVD. The
‘‘thrifty phenotype” hypothesis suggests that poor intrauter-
ine and infant nutrition produce permanent changes in
glucose-insulin metabolism, preparing the individual for a life
of starvation. Foetal malnutrition would result in insulin
resistance and poor development of pancreatic b-cell mass
and function. A limited insulin secretion capacity would not
be detrimental to those who remained poorly nourished and
thin, and, therefore, insulin sensitive. Nevertheless, if fol-
lowed by overnutrition in childhood and adult life, an adverse
foetal environment might lead to diabetes and other chronic
diseases [31].
Historical data suggest that South Asians have become
increasingly undernourished since the Mesolithic period.
These long-term intergenerational influences, especially
those adversely affecting maternal and/or early childhood,
may have increased their risk to diabetes [32]. Bavdekar
et al. [33] reported a significant association between low birth
weight and high insulin resistance in 8-year-old Indian chil-
dren. Other important contributing factors to diabetes sus-
ceptibility in this group include urbanization, decreased
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increased mental stress, and migration to more affluent
countries [34].
In recent history, several nations have suffered from fam-
ine. At the end of World War II (1944–1945), severe famine
affected the western region of the Netherlands. The Dutch
Hunger Winter Famine lasted 5 months, hit people of all
social classes and was followed by growing prosperity in the
post-war period. Moreover, it impacted foetal nutrition and
early development, with resulting epigenetic changes that
were linked to an increased risk of T2DM decades later [35].
Prenatal exposure to famine was related to impaired glucose
tolerance (IGT) in adulthood and this seemed to be mediated
by an insulin secretion defect [35,36].
Similar rises in the prevalence of T2DM have also been
observed years after famine in Ukraine [37], Cambodia [38]
and China [39]. Individuals exposed to the 1932–1933 Ukraine
Famine during early gestation were 1.5-fold more likely to
develop T2DM as adults than Ukrainians not affected by the
famine [37]. After decades of severe food shortages in 1975–
1979, T2DM prevalence in Cambodia rose to levels seen in
developed nations [38]. Foetal exposure to the Chinese famine
(1959–1961) exacerbated the association between obesity and
adult risk of incident T2DM, as well as the association
between hypertension and CVD [39].
2.4. Glycaemic response to carbohydrates in different
ethnic groups
The glycaemic index (GI) represents the ability of a carbohy-
drate food to raise blood glucose levels [40]. It has been
assumed that the glycaemic potential of certain food is inde-
pendent of metabolic or demographic differences of the con-
sumer. Nevertheless, different glycaemic responses to the
same carbohydrate-containing food or glucose load have been
reported across populations [41]. Venn et al. [41] observed that
Asians present higher glycaemic responses than Caucasians
following a common breakfast cereal (63% higher) and a bev-
erage containing 50 g of glucose (29% higher). For an identical
carbohydrate load, South Asians exhibit postprandial glucose
peaks that are 2–3 times larger than Caucasians [40]. Further-
more, it has been reported that Hispanics have lower gly-
caemic excursions after evening meals than Caucasians,
whereas Asians show greater excursions after breakfast than
Caucasians [42]. Thai, Vietnamese, and Chinese lean young
adults showed significantly higher postprandial glycaemia
than European Caucasians after a bread meal (75 g carbohy-
drate) [43].
Traditional Asian diets are known to improve postprandial
glucose profile at similar calories and even at greater carbohy-
drate content than Western diets [44]. Further, low GI Asian
meals were shown to improve glycaemic response and even
to increase fat oxidation [45]. Until the early 1970s, most tra-
ditional Asian diets were less milled or polished. Undermilled
rice is nutritionally superior (richer in fibre, polyphenols, and
vitamin E) than the fully milled white rice. However, during
the last decades, hand-pounded rice has been increasingly
replaced with white rice in many Asian countries. A recent
study of 132,373 participants has shown that higher con-sumption of white rice is associated with an increased risk
of incident diabetes in South Asia [46]. Ethnic differences
have been observed in glycaemic responses to several vari-
eties of rice. Kataoka et al. [47] reported that Chinese people
had 60% greater glycaemic responses for five rice varieties
than Europeans. Additionally, the GI for four rice varieties
was approximately 20% greater in the Chinese [47].
Ethnicity is therefore an important factor in the contribu-
tion of postprandial glucose to glycated haemoglobin (HbA1c)
levels. Given the higher intake of carbohydrates and greater
glycaemic responses to the same glycaemic load in Asians,
it is likely that they may have different insulin requirements
especially higher mealtime insulin doses. Overall, more well-
designed studies should be conducted in different popula-
tions to elucidate how dietary carbohydrates could be tar-
geted to optimize blood glucose regulation. Including low GI
foods may benefit Asians who habitually consume higher
refined carbohydrate cereal staple diets than Europeans.
2.5. Race/ethnic differences in determinants of insulin
resistance and secretion
Ethnic differences have been consistently observed on the
mean values of height, weight, body mass index (BMI), body
composition, and fat distribution. In general, Africans have
less visceral fat area but more skeletal muscle and bone min-
eral mass than Caucasians, even though they tend to have
similar body sizes [7]. On the other hand, East Asians have
smaller mean height, weight, BMI and less mean total visceral
fat volume than Africans and Caucasians [48]. South Asians
often present higher body fat and lower lean muscle mass
at the same or lower BMIs compared with white people (the
‘‘high body fat-normal weight/BMI-low muscle mass” pheno-
type) [49].
Although Africans have less intra-abdominal visceral fat
than Caucasians, it has been observed that they are more
insulin resistant, have greater insulin secretion and lesser
insulin clearance than white people [50]. In this scenario, the
expected positive association between visceral fat and insulin
resistance is not applied. Nevertheless, it is possible that the
African’s large amount of muscle and bone mass affects insu-
lin sensitivity determinants, potentially leading to insulin
resistance and increased insulin response. A higher baseline
insulin secretion or lower insulin clearancemay be also neces-
sary to keep and grow the great amount of muscle and bone in
this population [7]. Additionally, it has been observed that
Africans have lower ectopic and greater peripheral (gluteo-
femoral) fat deposition than their European counterparts. This
may indicate that either Africans are more sensitive to the
effects of ectopic fat deposition or that ectopic fat is not an
important mediator of T2DM in this population [50].
As addressed previously, healthy East Asians have a lower
AIRg compared with Africans and Caucasians. It is likely that
this may be a consequence of either 1) high insulin sensitivity
due to low visceral fat content in healthy individuals or 2)
lower baseline insulin secretion or higher insulin clearance
sufficient to maintain a smaller body size compared with
the other two groups. Furthermore, in the transition from
NGT to IGT, insulin sensitivity may be markedly reduced,
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 5 ( 2 0 2 1 ) 1 0 8 8 2 3 7while insulin response does not change significantly in East
Asians. Nevertheless, insulin response may be rapidly
reduced from IGT to T2DM [7].
It has been suggested that the pathogenesis of T2DM may
differ in Asian populations compared with Caucasians. T2DM
develops in Asian patients at a younger age and lower levels
of BMI and waist circumference than white populations
[51,52]. In fact, the BMI cutoff points for normal weight, over-
weight, and obesity were revised for Asians, and are now
lower than the international classification criteria [53]. South
Asians are disproportionally predisposed to diabetes. The
underlying risk factors include higher insulin resistance,
impaired b-cell function, an abnormal adipokine profile, and
certain high risk genetic polymorphisms [34]. In the 1980s,
Mohan et al. [54] observed that basal insulin levels and insulin
response to a glucose load were higher in Asian Indians than
Europeans. These results indicated that Asian Indians need
higher levels of insulin to maintain euglycaemia and secrete
higher amounts of insulin in response to the same glucose
load [54]. Scholfield et al. [55] reported that Asian Indian veg-
etarians had significantly higher insulin levels than American
vegetarians both in the fasting state and after an oral glucose
load. Although they presented comparable diets, Asian Indi-
ans were more likely to be insulin resistant [55].
Given the same BMI, South Asians have higher total body
fat and abdominal adipose tissue (both subcutaneous and vis-
ceral fat) than Caucasians [49]. This tendency to abdominal
adiposity can result in increased fatty acid influx to the liver,
impaired adipokine production, fatty liver, and hepatic insu-
lin resistance [49,56]. Ectopic hepatic and intramyocellular
fat deposition are important determinants of insulin resis-
tance, which may propagate a vicious cycle with higher ecto-
pic fat deposition in the liver and islets, hepatic insulin
resistance, b-cell dysfunction and T2DM [49,57]. It has beenFig. 2 – Racial differences in achieving HbA1c level < 7% with  1
and double asterisk p < .01 vs Caucasians. BASAL = insulin glar
mix 75/25 twice daily; LMTID = insulin lispro mix 50/50 three ti
creative commons license.suggested that this predisposition to adiposity and insulin
resistance begins during foetal development. Yajnik et al.
[58] found that Indian babies were lighter and smaller than
babies born in the U.K., but preserved body fat (the thin–fat
Indian baby). This body compositionmight persist later in life,
resulting in an insulin-resistant state [58].
Asians have shown a decreased insulin secretion capacity
which further increases the risk of diabetes [7,32]. The under-
lying mechanisms are yet to be determined; however, it may
be explained by lower b-cell mass, impaired b-cell function
and/or genetic influences [32]. In the US, it was observed that
non-diabetic adult South Asians and Chinese had the lowest
insulin secretion, compared with Hispanics, African Ameri-
cans, andwhites [4]. In the pathogenesis of T2DM, it is usually
described that high insulin resistance may trigger increased
insulin production to maintain normoglycaemia, which can
result in b-cell failure over the time. Nevertheless, in Asian
Indians, b-cell dysfunction appears to be the primary aetio-
logical factor in the development of T2DM [59]. Therefore, tar-
geted interventions to preserve or improve beta cell function
and specific pharmacological approaches may be necessary in
this population.
2.6. Efficacy and safety of insulin therapy by race/ethnicity
Race/ethnicity poses a challenge for optimal treatment in
T2DM patients. So far, most clinical trials have been con-
ducted primarily among white individuals. The lack of
racially/ethnically diverse participants in diabetes clinical tri-
als raises concern for the efficacy and safety of a given insulin
regimen in different populations [42].
In a post hoc analysis of pooled data from 11multinational
clinical trials involving 1455 patients with T2DM, the meta-
bolic response to insulin therapy differed significantly across2 weeks of insulin therapy. Single asterisk indicates p < .05
gine or neutral protamine Hagedorn; LMBID = insulin lispro
mes daily. Figure by Davidson et al. [42]. Non-commercial
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sity. Hispanics showed better glycaemic control than Cau-
casians with a 12- to 24-week regimen of basal therapy.
Nevertheless, after 12 to 16 weeks of insulin lispro mix
75/25 twice daily, Hispanic, and Asian patients had poorer
overall glycaemic control than Caucasians (Fig. 2). Further-
more, Asians experienced higher incidence and rate of severe
hypoglycaemia than Caucasians with intensified premixed
insulin therapy (insulin lispro mix 50/50 three times daily)
[42]. In a retrospective case analysis of 280 T2DM patients
treated for 12 months with insulin (regimen not specified),
significantly greater HbA1c reductions were observed in Afri-
can/Caribbean patients than in Caucasians or Asians, despite
significantly smaller weight-adjusted insulin doses [60].
It has been reported that glycaemic control varies signifi-
cantly by race/ethnicity. Despite controlling for factors affect-
ing glycaemia, HbA1c levels are often significantly higher in
non-Caucasians with T2DM, IGT or NGT. In a clinical trial
involving 2094 patients from 11 countries, HbA1c was signifi-
cantly higher in Hispanics, Asians, Africans, and patients of
other racial/ethnic groups than Caucasians [61]. In a meta-
analysis by Kirk et al. [62], African Americans and Hispanics
had higher HbA1c values than NHW, independently of study
design, data collection methodology, and type of medical
care. The higher therapeutic failures in non-white popula-
tions [63] may suggest that ethnic-based insulin dosing and
formulations are needed.
3. Conclusions
Until now, racial/ethnic-specific clinical practice recommen-
dations are limited in international guidelines. Few studies
have addressed outcome differences in glycaemic control
related to race/ethnicity and specific insulin regimens.
It has been shown that treatment response to insulin ther-
apy varies by race/ethnicity and warrants future large trials.
Future prospective clinical trials should include subjects in
their natural habitat (for instance, Africans in Africa, South
Asians in South Asia, Chinese in China) and where they
migrated to, as well as Europeans, South and Central Ameri-
cans, etc. This kind of study should be conducted under Inter-
national respected bodies, like IDF or in collaboration with the
World Health Organization (WHO). The trials should be tar-
geted to the efficacy and safety of different insulin regimens
in diverse populations, considering their body and fat compo-
sition and specific food habits.
Given the high and increasing prevalence of T2DM partic-
ularly in non-white populations, more studies are needed to
better understand the impact of race/ethnicity on the differ-
ential responses to insulin therapy. This may provide more
personalized and targeted management strategies.
Definition of race/ethnic groups
South Asian: refers to Asian Indian, Pakistani, Sri Lankan,
Bangladeshi, Nepali, Bhutanese, Afghan, and Maldivian. East
Asian: refers to Japanese, Chinese, and Korean. Southeast
Asian: refers to Filipino, Vietnamese, Cambodian, Laotian,
Thai, Indonesian, Malaysian, Singaporean, and Hmong. His-panic: refers to Puerto Rican, Cuban or Cuban American,
Dominican (Republic), Mexican or Mexican American, Central
or South American. Non-Hispanic Black (NHB): individuals of
African descent or who self-identify as black or African Amer-
ican. Non-Hispanic Asian: non-Hispanic persons who do not
self-identify as black and have origins in any of the Asian
countries. Non-Hispanic White (NHW): non-Hispanic individ-
uals not falling into the other categories who self-identify as
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